Phase III Trial Completed: Digital Therapeutics CT-155 as Adjunct to Antipsychotics for Negative Symptoms in Schizophrenia — Results Pending

References

1. 1.Click Therapeutics, Inc. (2024). A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05838625
2. 2.Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 16, 519-534. https://doi.org/10.2147/NDT.S225643
3. 3.Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015). Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin, 41(4), 892-899. https://doi.org/10.1093/schbul/sbu170
4. 4.Galderisi, S., Mucci, A., Buchanan, R. W., & Arango, C. (2018). Negative symptoms of schizophrenia: new developments and unanswered research questions. The Lancet Psychiatry, 5(8), 664-677. https://doi.org/10.1016/S2215-0366(18)30050-6
5. 5.Kring, A. M., Gur, R. E., Blanchard, J. J., Horan, W. P., & Reise, S. P. (2013). The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. American Journal of Psychiatry, 170(2), 165-172. https://doi.org/10.1176/appi.ajp.2013.12010109
6. 6.Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophrenia Research, 137(1-3), 147-150. https://doi.org/10.1016/j.schres.2012.08.015